Provided by Tiger Fintech (Singapore) Pte. Ltd.

Portage Biotech Inc.

6.81
0.0000
Volume:- -
Turnover:- -
Market Cap:15.52M
PE:-1.19
High:6.81
Open:6.81
Low:6.81
Close:6.81
52wk High:23.01
52wk Low:2.81
Shares:2.28M
Float Shares:1.43M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.7202
EPS(LYR):-5.7202
ROE:-541.81%
ROA:-92.69%
PB:-126.16
PE(LYR):-1.19

Loading ...

Company Profile

Company Name:
Portage Biotech Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.